Inborn Errors of Metabolism: Pathway-Block Reasoning Guide

Short version. An inborn error of metabolism is a heritable defect in an enzyme, transporter, or cofactor-handling protein that disturbs a defined metabolic pathway. The result, traceable through the pathway-block model, is some combination of upstream substrate accumulation, downstream product depletion, and shunting through alternative pathways — with phenotype following the biochemistry. The catalogue runs to several hundred named disorders; modern population programmes detect a curated subset at birth using tandem mass spectrometry on a dried blood spot, and clinical exome sequencing has become the default next step where the first-line biochemical work-up is unrevealing.

Definition and the pathway-block model

An inborn error of metabolism (IEM) is a heritable defect in a protein that has a metabolic role — most commonly an enzyme, but also a membrane transporter, a cofactor-binding or cofactor-recycling protein, or a regulatory subunit. The defect causes one or more of three biochemical signatures: accumulation of substrate upstream of the block; depletion of product downstream; and activation of, or accumulation in, alternative pathways that handle the surplus substrate. The clinical phenotype is the integrated consequence of these three.

This is the model Sir Archibald Garrod set out in his 1902 Lancet paper on alkaptonuria, "The incidence of alkaptonuria: a study in chemical individuality" (Garrod 1902), and elaborated in his 1923 monograph Inborn Errors of Metabolism, which named the field. Garrod observed that affected children excreted homogentisic acid — a tyrosine-pathway intermediate — in urine that turned black on standing, and that the trait clustered in sibships from cousin marriages, consistent with Mendelian recessive inheritance. The molecular target, homogentisate 1,2-dioxygenase, was not identified until 1996; but the inferential structure Garrod sketched in 1902 — specific enzyme deficiency, predictable substrate / product disturbance, predictable inheritance — is the same one that is taught today.

Beadle and Tatum's Neurospora crassa auxotroph experiments forty years later (Beadle and Tatum 1941, PNAS 27:499) provided the molecular generalisation: each gene specifies the structure of one enzyme. The synthesis of Garrod's pathway-block reasoning with the one-gene-one-enzyme principle is the conceptual scaffold of modern metabolic genetics.

The major disease groups

The catalogue is conventionally organised by the metabolic pathway each disorder disrupts. The major groups, with representative disorders:

Amino-acid disorders

Defects in the catabolism of individual amino acids. Phenylketonuria (PKU), deficiency of phenylalanine hydroxylase, was the disorder for which population newborn screening was first established. Untreated, accumulating phenylalanine produces neurotoxicity; the dietary intervention — phenylalanine restriction from infancy — is the canonical example of how mechanistic understanding translates into management. Tyrosinaemia type I, fumarylacetoacetate hydrolase deficiency, produces hepatic and renal disease and is treated with nitisinone (NTBC), a small-molecule blocker of an upstream enzyme that prevents the toxic intermediates from accumulating — a textbook substrate-reduction approach. Maple syrup urine disease (MSUD) is a defect of the branched-chain α-ketoacid dehydrogenase complex, with accumulation of leucine, isoleucine, and valine; the urine carries the characteristic odour. Homocystinuria classically reflects cystathionine β-synthase deficiency.

Urea-cycle defects

Six enzyme steps convert ammonia and aspartate to urea for excretion. Deficiency at any step causes hyperammonaemia, with neurological consequences. Ornithine transcarbamylase (OTC) deficiency is the most common; it is X-linked, distinctive in a field that is otherwise predominantly autosomal recessive, and shows variable expressivity in heterozygous females depending on X-inactivation patterns. Citrullinaemia reflects argininosuccinate synthase deficiency; argininosuccinic aciduria (ASA) reflects argininosuccinate lyase deficiency; arginase deficiency presents later, with a progressive spastic diplegia phenotype rather than the neonatal encephalopathy typical of the more proximal blocks.

Organic acidaemias

Defects in the catabolism of branched-chain amino acids and odd-chain fatty acids produce accumulation of organic acid intermediates. The classic trio is methylmalonic acidaemia (methylmalonyl-CoA mutase deficiency or its B12 cofactor pathway), propionic acidaemia (propionyl-CoA carboxylase deficiency), and isovaleric acidaemia (isovaleryl-CoA dehydrogenase deficiency, with a distinctive sweaty-feet body odour). All three present, untreated, with a neonatal metabolic acidosis with high anion gap, hyperammonaemia, and ketosis.

Fatty acid oxidation defects

The mitochondrial β-oxidation spiral progressively shortens fatty acyl-CoA chains; defects at successive chain-length-specific dehydrogenases produce medium-chain (MCAD), long-chain hydroxyacyl-CoA (LCHAD), and very-long-chain (VLCAD) acyl-CoA dehydrogenase deficiencies. The classical presentation is hypoketotic hypoglycaemia in fasting or intercurrent illness; MCAD is the most common, picked up routinely on tandem mass spectrometry newborn screening as elevated C8 acylcarnitine.

Lysosomal storage disorders

Defects in lysosomal acid hydrolases or their trafficking machinery cause progressive intra-lysosomal substrate accumulation in tissue-specific patterns. Tay-Sachs disease (hexosaminidase A deficiency) and the related Sandhoff and GM1 gangliosidoses produce a progressive neurodegenerative phenotype. Gaucher disease (glucocerebrosidase deficiency) is the most common; type 1, with hepatosplenomegaly and bone disease but without primary CNS involvement, was the first lysosomal disorder to be addressed by enzyme-replacement therapy. Fabry disease (α-galactosidase A deficiency) is X-linked and affects vascular endothelium. Pompe disease (acid α-glucosidase deficiency) causes glycogen accumulation in cardiac and skeletal muscle. The mucopolysaccharidoses (MPS I Hurler, MPS II Hunter, MPS III Sanfilippo, MPS IV Morquio, MPS VI Maroteaux-Lamy, MPS VII Sly) reflect deficiency of glycosaminoglycan-degrading enzymes, with skeletal and connective-tissue manifestations and, in many subtypes, CNS involvement. The Niemann-Pick spectrum spans acid sphingomyelinase deficiency (types A and B) and the cholesterol-trafficking defect of Niemann-Pick type C.

Peroxisomal disorders

The peroxisome handles very-long-chain fatty acid β-oxidation, plasmalogen synthesis, and bile acid intermediates. X-linked adrenoleukodystrophy (X-ALD), ABCD1 transporter deficiency, produces accumulation of very-long-chain fatty acids and a progressive demyelinating phenotype with adrenal insufficiency. The Zellweger spectrum — PEX-gene defects of peroxisome biogenesis — produces the multisystem severe phenotype of Zellweger syndrome through to the milder neonatal adrenoleukodystrophy and infantile Refsum phenotypes.

Mitochondrial disorders

The respiratory chain is unusual in being encoded across two genomes — nuclear and mitochondrial. The mitochondrial-DNA disorders, transmitted through the maternal line and influenced by heteroplasmy, include MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy with ragged-red fibres), LHON (Leber's hereditary optic neuropathy), Leigh syndrome (subacute necrotising encephalomyelopathy; nuclear and mtDNA forms), NARP (neuropathy, ataxia, retinitis pigmentosa), and Kearns-Sayre syndrome (typically large-scale single mtDNA deletions). The non-Mendelian transmission has its own dedicated pedigree-modelling page at mitochondrial inheritance pedigree.

Glycogen storage diseases

Defects in glycogen synthesis, mobilisation, or degradation produce tissue-specific accumulation of structurally normal or abnormal glycogen. Glycogen storage disease type I (von Gierke), glucose-6-phosphatase deficiency, presents with fasting hypoglycaemia, hepatomegaly, and lactic acidosis. GSD type II (Pompe) is also a lysosomal storage disorder. GSD type V (McArdle), myophosphorylase deficiency, produces exercise-induced muscle pain and rhabdomyolysis.

Congenital disorders of glycosylation (CDG)

Defects in the assembly, transfer, or processing of the N- and O-linked glycan chains attached to most secreted and membrane-bound proteins. The CDG-Ia subtype (PMM2 deficiency) is the most common N-glycosylation defect; MPI-CDG (CDG-Ib, phosphomannose isomerase deficiency) is treatable with oral mannose, an unusual feature in this group.

Newborn screening: from Guthrie to tandem mass spectrometry

Robert Guthrie's bacterial inhibition assay, developed at the Buffalo Children's Hospital in the late 1950s and reported with Susi in 1963, allowed phenylalanine to be measured from a few drops of blood collected on filter paper at the heel of the newborn (Guthrie and Susi 1963). The Guthrie card — the dried blood spot — remains the standard sample format six decades later, although the analytical method has changed: tandem mass spectrometry, applied to dried-blood-spot eluates, can now quantify dozens of acylcarnitines and amino acids in a single run, identifying fatty-acid-oxidation defects, organic acidaemias, urea-cycle defects, and amino-acid disorders alongside PKU.

The two most widely cited reference panels for the breadth of population programmes are the United States Recommended Uniform Screening Panel (RUSP) and the conditions in the UK NHS Newborn Blood Spot Screening programme. Levy's review (Levy 2010, Nat Rev Genet 11:725) provides a still-useful overview of how newborn screening grew from one disorder in 1963 to the multiplex panels of the present.

Newborn screening produces a positive screen, not a diagnosis. Confirmation requires a second-tier biochemical or molecular test, and many borderline screens reflect benign maternal or transient neonatal patterns rather than disease. The educational point worth emphasising in teaching is the screen-test-confirm-test sequence, with its different operating characteristics at each step.

The diagnostic odyssey and the role of exome sequencing

For disorders not picked up through population screening, or for atypical presentations of screened disorders, the diagnostic pathway has historically run through targeted biochemical testing — quantitative urinary organic acids, plasma amino acids, acylcarnitine profiles, very-long-chain fatty acids, lysosomal enzyme assays in leucocytes — and then, where these are unrevealing, gene-by-gene Sanger sequencing of candidate loci. The "diagnostic odyssey" is the term clinicians use for the long sequence of tests that this can become.

Clinical exome sequencing changed the shape of that odyssey. Yang et al. 2013, NEJM 369:1502 reported a 25 percent diagnostic yield in 250 unselected patients referred to a CLIA-certified laboratory exome service, with metabolic and neurodevelopmental phenotypes well represented in the diagnoses returned. Subsequent series have placed yields in similar ranges — 25 to 35 percent — depending on phenotype selection and the depth of prior work-up. In contemporary clinical-genetics services, exome sequencing is often the first molecular test in a child with a complex undiagnosed metabolic phenotype, with biochemical testing then directed by the variant findings rather than the other way around.

The textbook reference for the catalogue and its diagnostic logic is Saudubray, Baumgartner, and Walter's Inborn Metabolic Diseases: Diagnosis and Treatment (Springer, 6th edition 2016). The continuously updated open-access reference is OMIM (omim.org), with GeneReviews chapters at the NCBI Bookshelf for many of the named disorders.

Inheritance patterns and the role of pedigree documentation

The majority of inborn errors of metabolism are autosomal recessive. The autosomal-recessive pattern in a pedigree shows, classically, affected individuals confined to a single sibship, with unaffected obligate-carrier parents and, often, consanguinity in the parental generation. Population-specific carrier frequencies are part of the educational picture: Tay-Sachs in Ashkenazi Jewish, French Canadian, and Cajun populations; sickle cell and the α / β thalassaemias across sub-Saharan Africa, the Mediterranean, and South Asia; the founder-effect MPS-I and MPS-II variants in particular communities. Evagene's autosomal recessive calculator illustrates the standard 1-in-4 sibling recurrence and the 2-in-3 unaffected-sibling carrier-probability calculation; the consanguinity calculator illustrates how shared ancestry raises the probability of homozygosity at any rare allele.

The notable exceptions to autosomal-recessive inheritance are X-linked: ornithine transcarbamylase deficiency, X-linked adrenoleukodystrophy, Fabry disease, Lesch-Nyhan syndrome, MPS II (Hunter syndrome). For these, female heterozygotes can be variably affected, and the structured pedigree carries genuinely useful information. The mitochondrial-DNA disorders, transmitted maternally and influenced by heteroplasmy, are the third pattern; they are treated separately under mitochondrial inheritance pedigree on this site.

Selected references

Garrod, A. E. (1902). The incidence of alkaptonuria: a study in chemical individuality. Lancet 160:1616–1620. DOI
Beadle, G. W., and Tatum, E. L. (1941). Genetic control of biochemical reactions in Neurospora. PNAS 27:499–506. DOI
Guthrie, R., and Susi, A. (1963). A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338–343. PubMed
Yang, Y. et al. (2013). Clinical whole-exome sequencing for the diagnosis of mendelian disorders. NEJM 369:1502–1511. PubMed
Saudubray, J.-M., Baumgartner, M. R., and Walter, J. H. (eds.) (2016). Inborn Metabolic Diseases: Diagnosis and Treatment (6th edition). Springer. Springer
Levy, H. L. (2010). Newborn screening conditions: what we know, what we do not know, and how we will know it. Nat Rev Genet 11:725–733. PubMed
Online Mendelian Inheritance in Man (OMIM). omim.org
GeneReviews, NCBI Bookshelf. ncbi.nlm.nih.gov/books/NBK1116/

Inborn errors of metabolism